Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
By Adria Calatayud
Novartis struck a deal valued at up to $7.8 billion to license a drug candidate from China's Abogen Biosciences and gain options over future therapies, the latest tie-up between a big Western drugmaker and a Chinese upstart.
The Swiss drugmaker is paying $575 million upfront and could make additional payments of up to $7.2 billion if options on all programs are exercised, Abogen said Friday.
Under the deal, Novartis will acquire worldwide rights over Abogen's lead drug candidate, called ABO2203, and get an exclusive option to license other next-generation therapeutic assets developed on Abogen's RNA platform, the Chinese company said.
Abogen said its lead drug has potential to transform the treatment landscape for patients with autoimmune diseases. The drug uses messenger RNA to boost the body's production of a type of antibodies.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
October 02, 2026 06:50 ET (10:50 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States